CA2839298C - Anti-inflammatory pharmaceutical products - Google Patents

Anti-inflammatory pharmaceutical products Download PDF

Info

Publication number
CA2839298C
CA2839298C CA2839298A CA2839298A CA2839298C CA 2839298 C CA2839298 C CA 2839298C CA 2839298 A CA2839298 A CA 2839298A CA 2839298 A CA2839298 A CA 2839298A CA 2839298 C CA2839298 C CA 2839298C
Authority
CA
Canada
Prior art keywords
residues
human annexin
pharmaceutical products
terminal
inflammatory pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2839298A
Other languages
English (en)
French (fr)
Other versions
CA2839298A1 (en
Inventor
Angelo P. Consalvo
Nozer M. Mehta
Mauro Perretti
Jesmond DALLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resother Pharma AS
Original Assignee
Resother Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resother Pharma AS filed Critical Resother Pharma AS
Publication of CA2839298A1 publication Critical patent/CA2839298A1/en
Application granted granted Critical
Publication of CA2839298C publication Critical patent/CA2839298C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2839298A 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products Active CA2839298C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161497270P 2011-06-15 2011-06-15
US61/497,270 2011-06-15
PCT/US2012/042699 WO2012174397A2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products
US13/524,381 2012-06-15
US13/524,381 US9102753B2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products

Publications (2)

Publication Number Publication Date
CA2839298A1 CA2839298A1 (en) 2012-12-20
CA2839298C true CA2839298C (en) 2021-05-18

Family

ID=47357770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2839298A Active CA2839298C (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products

Country Status (12)

Country Link
US (2) US9102753B2 (https=)
EP (2) EP3533457B1 (https=)
JP (1) JP6069663B2 (https=)
CN (1) CN103764669B (https=)
AU (1) AU2012271453B2 (https=)
BR (1) BR112013032088B1 (https=)
CA (1) CA2839298C (https=)
DK (1) DK2720707T3 (https=)
ES (1) ES2712805T3 (https=)
HU (1) HUE042929T2 (https=)
PL (1) PL2720707T3 (https=)
WO (1) WO2012174397A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US9102753B2 (en) * 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
DK3244878T3 (da) 2015-01-12 2022-10-17 Enteris Biopharma Inc Faste orale sammensætningsformer
PL4200319T3 (pl) 2020-08-21 2025-08-18 Resother Pharma A/S Preparaty peptydu n-końcowego aneksyny a1 i sposoby
CN118891273A (zh) 2022-02-23 2024-11-01 雷索特制药股份有限公司 膜联蛋白a1衍生的多肽类似物
US20250345392A1 (en) 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
AU2024234229A1 (en) 2023-03-13 2025-09-25 Resother Pharma A/S Annexin a1 administration regime
EP4680262A1 (en) 2023-03-13 2026-01-21 Resother Pharma A/S Annexin a1 delayed dosing

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
WO1998046722A1 (en) 1997-04-16 1998-10-22 Unigene Laboratories Inc. Direct expression of peptides into culture media
US6086018A (en) 1997-12-09 2000-07-11 Mcdonnell Douglas Corporation Interlocking assembly system for an aircraft cabin
US20090163578A1 (en) * 2004-10-01 2009-06-25 University Of Medicine And Dentistry Of New Jersey Novel modification of immunomodulatory protein
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
AU2006261909B2 (en) 2005-06-24 2011-08-11 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
CN101287503A (zh) * 2005-08-03 2008-10-15 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
CN101273059B (zh) 2005-08-26 2014-02-19 艾伯维有限公司 治疗活性的α-MSH类似物
US8691764B2 (en) * 2007-03-28 2014-04-08 The Research Foundation For The State University Of New York Inhibitors of NF-κB activity
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
GB0724953D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Methods of peptide modification
EP2349321B1 (en) 2008-10-17 2020-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
US8940697B2 (en) * 2009-10-16 2015-01-27 Duke University Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with Annexin A1 short peptide
US9102753B2 (en) * 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products

Also Published As

Publication number Publication date
EP3533457B1 (en) 2021-08-11
CN103764669B (zh) 2017-08-15
ES2712805T3 (es) 2019-05-14
US20150315256A1 (en) 2015-11-05
US9102753B2 (en) 2015-08-11
BR112013032088B1 (pt) 2020-11-24
PL2720707T3 (pl) 2019-06-28
HUE042929T2 (hu) 2019-07-29
CN103764669A (zh) 2014-04-30
DK2720707T3 (en) 2019-04-08
AU2012271453A1 (en) 2013-12-19
CA2839298A1 (en) 2012-12-20
EP3533457A1 (en) 2019-09-04
EP2720707B1 (en) 2018-12-19
WO2012174397A2 (en) 2012-12-20
US10072055B2 (en) 2018-09-11
WO2012174397A3 (en) 2013-02-28
JP6069663B2 (ja) 2017-02-01
US20130072446A1 (en) 2013-03-21
JP2014519526A (ja) 2014-08-14
EP2720707A4 (en) 2015-05-06
BR112013032088A2 (pt) 2016-11-22
EP2720707A2 (en) 2014-04-23
AU2012271453B2 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
CA2839298C (en) Anti-inflammatory pharmaceutical products
PH12014501083A1 (en) Anticancer fusion protein
CL2012001686A1 (es) Analogo peptidico de oxintomodulina, en donde el aminoacido c-terminal es opcionalmente amidado; composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad.
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
PH12013500050A1 (en) Anticancer fusion protein
IN2014KN01713A (https=)
IN2014KN01714A (https=)
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
TW201613958A (en) MIC-1 fusion proteins and uses thereof
AR070119A1 (es) Derivados de insulina con perfil tiempo / accion extremadamente retardado
MX337436B (es) Proteina de funsion anticancer.
NZ600732A (en) Oxyntomodulin peptide analogue
WO2012158962A3 (en) Improved peptide pharmaceuticals
PH12013500715A1 (en) Anticancer fusion protein
MX352796B (es) Proteina de fusion anticancerigena.
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
PH12019550241A1 (en) Mic-1 compounds and uses thereof
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
GB201118201D0 (en) Novel peptides
JP2014519526A5 (https=)
EP4567043A3 (en) Compounds for inducing tissue regeneration and uses thereof
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
JP2017505772A5 (https=)
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
PH12015502005B1 (en) New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180508

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250521

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250521